Osteoporosis Drugs Market Size (2024 - 2029)

Osteoporosis Drugs Market Analysis

The Osteoporosis Drugs Market size is estimated at USD 16.12 billion in 2024, and is expected to reach USD 20.32 billion by 2029, at a CAGR of 4.74% during the forecast period (2024-2029).

The rising prevalence of osteoporosis, along with the growing geriatric population and fragility fractures, is expected to drive demand for effective treatment solutions. These demographic and health trends are anticipated to significantly contribute to the expansion of the osteoporosis drugs market. For instance, according to a report published in the Archives of Osteoporosis Journal in April 2024, the prevalence of osteoporosis is rising, showing a prevalence of 15.9% in individuals aged 50 and over, with a significant gender disparity. Many osteoporosis-related fractures remain undiagnosed, and only 30% of diagnosed individuals receive proper treatment, especially with a pronounced treatment gap in men. This increasing need for diagnosis and treatment directly fuels demand for osteoporosis drugs, driving market growth.

Furthermore, spinal cord injuries are associated with the development of osteoporosis. For instance, according to a report published in the BMC Medicine Journal in July 2024, the rising incidence of spinal cord injuries, with an overall incidence rate of 23.77 per million people, leads to increased mobility challenges and a higher risk of bone-related complications. As individuals with spinal cord injuries are prone to developing osteoporosis due to prolonged immobility, the need for effective therapeutic interventions is becoming more urgent. This growing demand for osteoporosis management solutions is propelling the expansion of the osteoporosis drugs market.

Additionally, the rising launches and approvals by the market players are expected to boost the market growth during the forecast period. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., received approval for a generic version of Forteo in the U.S. market. The teriparatide injection is indicated for the treatment of osteoporosis in select women and men. Similarly, in August 2022, the Ministry of Health, Labour, and Welfare (MHLW) approved the Edirol Tablet by Towa Pharmaceutical in Japan. Introducing new generic formulations and approvals of osteoporosis treatments enhances market accessibility and provides more therapeutic options, driving the growth of the osteoporosis drugs market by addressing unmet clinical needs.

In conclusion, the growth of the osteoporosis drugs market is driven by increasing incidences of osteoporosis, rising demand for effective treatments due to related fractures and injuries, and the introduction of new therapeutic formulations and approvals.

However, stringent approval and marketing regulations are expected to restrain the market growth.

Osteoporosis Drugs Industry Segmentation

As per the report's scope, osteoporosis drugs are pharmacological agents designed to prevent bone loss, enhance bone density, and reduce the risk of fractures in individuals with weakened skeletal structures due to reduced bone mass. These drugs typically work by either inhibiting bone resorption or stimulating bone formation, offering therapeutic solutions to manage and treat osteoporosis. The osteoporosis drugs market is segmented by drug type, application, and geography. The drug type is further divided into parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL Inhibitors, and other drug types. The application segment is further segmented into primary osteoporosis and secondary osteoporosis. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecast in value (USD) for the above segments.